Clinical characteristics and needle aspiration management of Bacillus Calmette-Guérin lymphadenitis in children

References

1. ↵
   1. WHO/UNICEF. Expanding immunization coverage

   Immunization, vaccines and biological, Available from URL: http://www.unicef.org/immunization/index_coverage.html. Updated 2014; Accessed 2014 September 4.
2. ↵
   1. Centers for Disease Control and Prevention. Morbidity and mortality weekly report

   Global routine vaccine coverage, Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6243a4.htm. Updated 2013 November 1, Accessed 2014 November 15.
3. ↵
   1. Hawn TR,
   2. Day TA,
   3. Scriba TJ,
   4. Hatherill M,
   5. Hanekom WA,
   6. Evans TG,
   7. et al.

   (2014) Tuberculosis vaccines and prevention of infection. Microbil Mol Biol Rev 78:650–671.

   OpenUrl
4. ↵
   1. Bukhari E,
   2. Alzahrani M,
   3. Alsubaie S,
   4. Alrabiaah A,
   5. Alzamil F

   (2012) Bacillus Calmette-Guerin lymphadenitis: A 6-year experience in two Saudi hospitals. Indian J Pathol Microbiol 55:202–205.

   OpenUrlPubMed
5. ↵
   1. Alrabiaah AA,
   2. Alsubaie SS,
   3. Bukhari EL,
   4. Gad A,
   5. Alzamel FA

   (2012) Outbreak of Bacille Calmette-Guérin-related lymphadenitis in Saudi children at a university hospital after a change in the strain of vaccine. Ann Saudi Med 32:4–8.

   OpenUrlPubMed
6. ↵
   1. Nuttall JJ,
   2. Davies MA,
   3. Hussey GD,
   4. Eley BS

   (2008) Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis 12:e99–e105.

   OpenUrlPubMedWeb of Science
7. ↵
   1. Duello-Garcia CA,
   2. Perez-Gaxiola G,
   3. Jemenez GC

   (2013) Treating BCG-induced disease in children. Cochrane Database Syst Rev, 10.1002/14651858.CD008300.pub2.
8. ↵
   1. Al-Salem AH,
   2. Kothari MR,
   3. Al Hani HM,
   4. Oquaish MM,
   5. Khogeer SS,
   6. Desouky MS

   (2012) Safety of intradermal Bacillus Calmette-Guerin vaccine for neonates in Eastern Saudi Arabia. Saudi Med J 33:172–176.

   OpenUrlPubMed
9. ↵
   1. Nelson KR

   1. Buckley RH

   (2008) in Nelson textbook of pediatrics, Evaluation of suspected immunodeficiency, ed Nelson KR (Elsevier Saunders, Philadelphia (PA)), 18th ed, pp 715–721.
10. ↵
    1. Dagg B,
    2. Hockley J,
    3. Rigsby P,
    4. Ho MM

    (2014) The establishment of sub-strain specific WHO Reference Reagents for BCG vaccine. Vaccine 32:6390–6395.

    OpenUrl
11. 1. Inamoto T,
    2. Ubai T,
    3. Nishida T,
    4. Fujisue Y,
    5. Katsuoka Y,
    6. Azuma H

    (2013) Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison. Urol Ann 5:7–12.

    OpenUrl
12. ↵
    1. Liu J,
    2. Tran V,
    3. Leung AS,
    4. Alexander DC,
    5. Zhu B

    (2009) BCG vaccines: Their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccine 5:70–78.

    OpenUrlCrossRef
13. ↵
    1. Ritz N,
    2. Tebruegge M,
    3. Streeton J,
    4. Curtis N

    (2009) Too much of a good thing: Management of BCG vaccine overdose. Vaccine 27:5562–5564.

    OpenUrl
14. 1. Antas PR,
    2. Castello-Branco LR

    (2008) New vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil. Trans R Soc Trop Med Hyg 102:628–630.

    OpenUrlCrossRefPubMed
15. ↵
    1. Dommergues MA,
    2. de La Rocque F,
    3. Guy C,
    4. Lécuyer A,
    5. Jacquet A,
    6. Guérin N,
    7. Fagot JP,
    8. et al.

    (2009) Local and regional adverse reactions to BCG-SSI®vaccination: A 12-month cohort follow-up study. Vaccine 27:6967–6973.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Plotkin SA,
    2. Orenstein WA,
    3. Offit P

    1. Smith KC,
    2. Orme IM,
    3. Starke JR

    (2013) in Vaccines, Tuberculosis. Tuberculosis vaccines, eds Plotkin SA, Orenstein WA, Offit P (WB Saunders, Philadelphia (PA)), 6th ed, pp 789–811.
17. ↵
    1. Chan WM,
    2. Kwan YW,
    3. Leung CW

    (2011) Management of Bacillus Calmette-Guérin Lymphadenitis. Hong Kong Journal of Paediatrics 16:85–94.

    OpenUrl
18. ↵
    1. Hawkridge A,
    2. Hatherill M,
    3. Little F,
    4. Goetz MA,
    5. Barker L,
    6. Mahomed H,
    7. et al.

    (2008) Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337:a2052.

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Sadeghi-Shanbestari M,
    2. Ansarin K,
    3. Maljaei SH,
    4. Rafeey M,
    5. Pezeshki Z,
    6. Kousha A,
    7. et al.

    (2009) Immunologic aspects of patients with disseminated bacille Calmette-Guerin disease in north-west of Iran. Ital J Pediatr 35:42.

    OpenUrlPubMed
20. ↵
    1. Sataynarayana S,
    2. Mathur AD,
    3. Verma Y,
    4. Pradhan S,
    5. Bhandari MK

    (2002) Needle aspiration as a diagnostic tool and therapeutic modality in suppurative lymphadenitis following Bacillus Calmette-Guerin vaccination. J Assoc Physicians India 50:788–791.

    OpenUrlPubMed
21. ↵
    1. Kim MS,
    2. Jo DS,
    3. Kyung KM,
    4. Kim SJ,
    5. Kim JS

    (2006) The effect of local rifampicin instillation on the treatment of suppurative BCG lymphadenitis. Korean J Pediatr 49:40–45.

    OpenUrl
22. ↵
    1. Juzi JT,
    2. Sidler D,
    3. Moore SW

    (2008) Surgical management of BCG vaccine-induced regional axillary lymphadenitis in HIV-infected children. S Afr J Surg 46:52–55.

    OpenUrlPubMed